News | April 24, 2023
Tissue engineered skin substitutes market to reach $3 billion by 2033, forecasts GlobalData
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
Clinical studies are expected to start in Q2 2023.
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
Theruptor Novo is a best in class patented product which provides an optimum healing environment and addresses the concerns of chronic wound dressing
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
Medical footprint expansion with deeper medical grade skin contact material science expertise
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Subscribe To Our Newsletter & Stay Updated
